1,7-phenanthroline has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hey, SM; Jensen, P; Kristensen, BW; Martínez Serrano, A; Meyer, M; Ryding, M | 1 |
| Blake, DR; Gutteridge, JM; Hall, M; Lunec, J; Pall, HS; Taylor, A; Williams, AC | 1 |
2 other study(ies) available for 1,7-phenanthroline and Parkinson Disease
| Article | Year |
|---|---|
Nonhypoxic pharmacological stabilization of Hypoxia Inducible Factor 1α: Effects on dopaminergic differentiation of human neural stem cells.
Topics: Benzimidazoles; Cell Differentiation; Cell Line; Dopaminergic Neurons; Fetus; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Mesencephalon; Neural Stem Cells; Parkinson Disease; Phenanthrolines; Prolyl-Hydroxylase Inhibitors; Pyrazoles | 2019 |
Raised cerebrospinal-fluid copper concentration in Parkinson's disease.
Topics: Adult; Copper; Female; Humans; Iron; Male; Manganese; Middle Aged; Parkinson Disease; Phenanthrolines; Severity of Illness Index; Spectrophotometry, Atomic | 1987 |